Epsilogen

London, United Kingdom

Epsilogen is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.

$16.3M raised

Sep 2024

Series B

Top Investors

Schroders CapitalEpidarex CapitalInnovate UKAlbionVC3B Future Health Fund

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Epsilogen raised?

Epsilogen has raised $16.3M in total funding. The most recent round was Series B. The last funding was announced in September 2024.

Who are Epsilogen's investors?

Epsilogen's investors include Schroders Capital, Epidarex Capital, Innovate UK, AlbionVC, 3B Future Health Fund.

Where is Epsilogen headquartered?

Epsilogen is headquartered in London, United Kingdom.

What does Epsilogen do?

Epsilogen is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.

What stage is Epsilogen at?

Epsilogen is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated September 9, 2024.

MLA

"Epsilogen — Funding & Investors." VCBacked, September 9, 2024, https://www.vcbacked.co/company/epsilogen. Accessed July 1, 2026.

APA

VCBacked. (2024). Epsilogen — Funding & Investors. Retrieved July 1, 2026, from https://www.vcbacked.co/company/epsilogen

Wikipedia (cite web)

{{cite web |title=Epsilogen — Funding & Investors |url=https://www.vcbacked.co/company/epsilogen |website=VCBacked |access-date=July 1, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated September 9, 2024.